Financial reports
10-Q
2024 Q1
Quarterly report
13 Feb 24
ARS
2023 FY
Annual report to shareholders
29 Jan 24
10-K
2023 FY
Annual report
15 Dec 23
10-Q
2023 Q3
Quarterly report
14 Aug 23
10-Q
2023 Q2
Quarterly report
12 May 23
10-Q
2023 Q1
Quarterly report
13 Feb 23
ARS
2022 FY
Annual report to shareholders
27 Jan 23
10-K
2022 FY
Annual report
21 Dec 22
10-Q
2022 Q3
Quarterly report
11 Aug 22
10-K/A
2021 FY
Annual report (amended)
31 May 22
Current reports
8-K
NeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation System
26 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
15 Mar 24
8-K
NeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
13 Feb 24
8-K
NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
14 Dec 23
8-K
NeuroOne® Receives FDA 510(k) Clearance to Market its OneRF™ Ablation System
11 Dec 23
8-K
NeuroOne® Announces Patent Allowance for Drug Delivery Utilizing a Novel Neural Probe
16 Nov 23
8-K
Volker strengthens existing management team in areas of commercialization, business development, and reimbursement
14 Nov 23
8-K
NeuroOne® Provides Progress Update on FDA 510(k) Submission for OneRF™ Ablation System
7 Nov 23
8-K
NeuroOne® Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
14 Aug 23
8-K
NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock
27 Jul 23
Registration and prospectus
S-8
Registration of securities for employees
31 Jan 24
424B5
Prospectus supplement for primary offering
5 Jan 24
S-8
Registration of securities for employees
15 Dec 23
424B5
Prospectus supplement for primary offering
1 Dec 23
424B5
Prospectus supplement for primary offering
26 Jul 23
424B5
Prospectus supplement for primary offering
24 Jul 23
424B5
Prospectus supplement for primary offering
24 Jul 23
S-8
Registration of securities for employees
22 Feb 23
424B5
Prospectus supplement for primary offering
22 Dec 22
S-8
Registration of securities for employees
28 Jan 22
Proxies
DEF 14A
Definitive proxy
29 Jan 24
DEF 14A
Definitive proxy
27 Jan 23
DEF 14A
Definitive proxy
29 Apr 22
DEF 14A
Definitive proxy
6 May 21
DEF 14A
Definitive proxy
1 May 20
PRE 14A
Preliminary proxy
16 Apr 20
DEF 14A
Definitive proxy
6 May 19
PRE 14A
Preliminary proxy
25 Apr 19
DEF 14A
Definitive proxy
27 Apr 18
SC 14F1
Statement regarding change in majority of directors
20 Jul 17
Other
EFFECT
Notice of effectiveness
15 Jun 21
CORRESP
Correspondence with SEC
10 Jun 21
UPLOAD
Letter from SEC
9 Jun 21
CERT
Certification of approval for exchange listing
25 May 21
EFFECT
Notice of effectiveness
9 Mar 21
CORRESP
Correspondence with SEC
5 Mar 21
CORRESP
Correspondence with SEC
4 Mar 21
UPLOAD
Letter from SEC
19 Feb 21
EFFECT
Notice of effectiveness
5 Oct 20
EFFECT
Notice of effectiveness
31 Aug 20